Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Phase II Clinical Trial to Study the Efficacy and Safety of a New Drug P276-00 in Treatment of Recurrent and/or Locally Advanced Head and Neck Cancer (MONARCH)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT00824343
Recruitment Status : Completed
First Posted : January 16, 2009
Last Update Posted : July 10, 2013
Sponsor:
Information provided by (Responsible Party):
Piramal Enterprises Limited

Tracking Information
First Submitted Date  ICMJE January 15, 2009
First Posted Date  ICMJE January 16, 2009
Last Update Posted Date July 10, 2013
Study Start Date  ICMJE September 2008
Actual Primary Completion Date April 2011   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: January 15, 2009)
Response rate [ Time Frame: Tumor measurements to be undertaken at baseline and at the end of every 2 cycles. Response evaluation to be performed on the basis of RECIST criteria ]
Original Primary Outcome Measures  ICMJE Same as current
Change History
Current Secondary Outcome Measures  ICMJE
 (submitted: January 15, 2009)
Duration of response, Progression free survival (PFS), Time to progression (TTP), PFS at one year, Overall survival (OS) at one year [ Time Frame: Tumor measurements at the end of every 2 cycles. Follow up for survival status every 4 weeks after discontinuation of protocol treatment till one year of cycle 1 day 1 ]
Original Secondary Outcome Measures  ICMJE Same as current
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE A Phase II Clinical Trial to Study the Efficacy and Safety of a New Drug P276-00 in Treatment of Recurrent and/or Locally Advanced Head and Neck Cancer
Official Title  ICMJE An Open Label, Multicenter Phase II Study to Evaluate Efficacy and Safety of P276-00 in Indian Subjects With Recurrent, Metastatic or Unresectable Locally Advanced Squamous Cell Carcinoma of Head and Neck
Brief Summary This is a single arm phase II trial to study the efficacy and safety of a Cdk inhibitor P276-00 in the treatment of squamous cell carcinoma of head and neck. Patients with recurrent or metastatic disease that is unresectable and incurable by radiation will be enrolled. Thirty eight evaluable patients need to be enrolled in the study. All patients will receive protocol treatment i.e. P276-00 as an intravenous infusion from day 1 to day 5 and from day 8 to day 12 in each 21 day cycle till progression of disease or unacceptable toxicity. Safety evaluations by means of recording vitals, physical examination and lab investigations like hematology and clinical chemistry will be undertaken at regular intervals in each cycle. Tumor measurements by spiral CT scan will be undertaken at baseline and at the end of every 2 cycles for response evaluation by RECIST criteria. All patients will be followed up for survival status till one year of cycle 1 day 1.
Detailed Description P276-00 was administered at a dose of 185mg/m2/day from day 1 to day 5 in each 21 day cycle. The protocol was amended in July 2009. As per the amendment P276-00 will be administered at a dose of 144 mg/m2/day from day 1 to day 5 and from day 8 to day 12 in each 21 day cycle till progression of disease or unacceptable toxicity.33 patients have been recruited in version 1 protocol, 38 more evaluable patients need to be recruited in version 2 protocol. Allowing for approximately 30% drop-outs, it is estimated that, for enrolling 38 evaluable subjects in the study, approximately 54 subjects would be enrolled. As the study has already enrolled 33 subjects, the sample size for the study to accommodate for same number of subjects (38 evaluable) in the revised protocol is estimated as approximately 87 (33 + 54) subjects. Hence the total sample size (accounting for drop-outs) is 87 patients.
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 2
Study Design  ICMJE Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE Squamous Cell Carcinoma of Head and Neck
Intervention  ICMJE Drug: P276-00
For patients to be recruited in amended protocol, P276-00 will be administered to all subjects at a dose of 144 mg/m2/day as i.v infusion in 200 ml of 5% dextrose over 30 minutes from day 1 to day 5 and from day 8 to day 12 in each 21 day cycle. Subjects will receive treatment till progression of disease or till unacceptable toxicity. All subjects will be followed up for survival status till one year of initiation of protocol treatment.
Study Arms  ICMJE Experimental: Single P276-00 arm
This is a single experimental arm study
Intervention: Drug: P276-00
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Completed
Actual Enrollment  ICMJE
 (submitted: July 8, 2013)
86
Original Estimated Enrollment  ICMJE
 (submitted: January 15, 2009)
54
Actual Study Completion Date  ICMJE June 2013
Actual Primary Completion Date April 2011   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  1. Age more than or equal to 18 years
  2. Subjects with histologically or cytologically confirmed SCCHN that is recurrent and/or metastatic and judged incurable by surgery and/or radiation therapy and with zero to one line of chemotherapy for recurrent or metastatic disease at least 60 days prior to study entry.
  3. Measurable disease, defined as at least one unidimensionally measurable lesion ≥ 20 mm by conventional techniques or ≥10 mm by spiral computerized tomography (CT) scan or magnetic resonance imaging (MRI)
  4. Tumor that is accessible to biopsy
  5. Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2
  6. Life expectancy of at least three months
  7. Hemoglobin ≥ 8.0 gm/dL
  8. Absolute neutrophil count (ANC) ≥ 1000/mm3
  9. Platelet count ≥ 50,000/mm3
  10. Total bilirubin ≤1.5X institutional upper limit of normal (ULN)
  11. Serum AST ≤ 3X institutional ULN
  12. Serum ALT ≤ 3X institutional ULN
  13. Serum creatinine ≤1.5X institutional ULN
  14. Ability to understand and the willingness to sign a written informed consent document (ICD)

Exclusion Criteria:

  1. Nasopharyngeal carcinoma
  2. Prior treatment with P276-00 or other Cyclin dependent kinase (CDK) targeting agents
  3. History of allergic reactions attributed to compounds of similar chemical composition to P276-00
  4. Subjects who have received radiotherapy, chemotherapy or biologic/targeted anticancer agents within 60 days prior to Day 1 of study drug administration or have not recovered from adverse effects of any prior radiotherapy, chemotherapy or biologic/targeted agents.
  5. More than one chemotherapy regimen for the recurrent or metastatic disease
  6. Subjects who had received any other investigational drug within 1 month or within five half-lives of the other investigational agent, whichever is longer prior to Day 1 of study drug administration
  7. Subjects with QTc > 450 msec on 12 lead standard electrocardiogram (ECG)
  8. History of unstable angina or myocardial infarction or stroke within previous 6 months
  9. Subjects with uncontrolled inter-current illness including, but not limited to active infection, symptomatic congestive heart failure, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
  10. Subjects known to be suffering from infection with HIV, Tuberculosis, Hepatitis C or Hepatitis B
  11. Known brain metastasis
  12. History of prior malignancy except for curatively treated basal cell or squamous cell carcinoma of skin, in situ cervical cancer, in situ breast cancer, in situ prostate cancer or any other cancer for which the subject has been disease-free for at least 3 years
  13. Women who are pregnant or lactating
  14. Women of childbearing potential [defined as sexually mature women who have not undergone hysterectomy or who have not been naturally postmenopausal for at least 24 consecutive months (i.e. who have had menses any time in the preceding 24 consecutive months)] and men, not agreeing to use adequate contraception (e.g., hormonal or barrier method of birth control or abstinence) prior to study entry (after signing the ICD), during the period of study participation and for at least 4 weeks after withdrawal from the study, unless they are surgically sterilized
  15. Any condition, including laboratory abnormalities, that in the opinion of the Investigator places the subject at an unacceptable risk or deems the subject not suitable for participation in the study
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE India
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT00824343
Other Study ID Numbers  ICMJE P276-00/21/08
Has Data Monitoring Committee No
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE Not Provided
Responsible Party Piramal Enterprises Limited
Study Sponsor  ICMJE Piramal Enterprises Limited
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Principal Investigator: Dr. Ajay Mehta Director and Onco-Surgeon, Central India Cancer Research Institute, Nagpur
Principal Investigator: Dr. M S Vishveshwara Radiation Oncologist, Bharat Hospital Institute of Oncology, Mysore
Principal Investigator: Dr. Sanjeev Misra Oncosurgeon, Department of Surgical Oncology, CSM Medical University, Lucknow
Principal Investigator: Dr. Rejnish Kumar Associate Professor, Regional Cancer Centre, Trivandram
Principal Investigator: Dr. Lalit Mohan Sharma Consultant Medical Oncologist, Bhagwan Mahavir Cancer Hospital and Research Centre, Jaipur
Principal Investigator: Dr. Maheboob Basade Medical Oncologist, Jaslok Hospital, Mumbai
Principal Investigator: Dr. Nilesh Lokeshwar, MD, DM Medical Oncologist
Principal Investigator: Dr. Chetan Deshmukh, MD, DM Medical Oncologist, Deenanath Mangeshkar Hospital and Research Centre, Pune, India
Principal Investigator: Dr. M Nagarajan, MD Radiation Oncologist, V. N. Cancer Centre, GKNM Hospital, Coimbatore, India
PRS Account Piramal Enterprises Limited
Verification Date July 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP